InflaRx IFRX 深 滬
等待開盤 09-25 09:30:00 美东时间
1.9302
-0.030
-1.52%
華盛通- 最 高2.02
- 今 開1.97
- 成交量 40.00万股
- 最 低 1.89
- 昨 收 1.96
- 總市值 2.84亿
- 52周最高 2.9489
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 0.7984
- 委 比 -25.69%
- 總股本 1.47亿
- 歷史最高 53.10
- 量 比 0.95
- 振 幅 6.63%
- 歷史最低 0.7113
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多InflaRx to Host Virtual Capital Markets Day
InflaRx N.V. will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST to 9:00 AM EST, featuring Peter A. Merkel, MD, MPH, and Prof. Dr. Jörg Köhl. The event will discuss ANCA-associated vasculitis (AAV), the evolving treatment landscape, and the potential of izicopan, an orally administered C5a receptor inhibitor, to improve the standard of care. Key topics include InflaRx's development strategy, clinical program updates, a...
09-21 11:30
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
Needham Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $8
Needham analyst Joseph Stringer initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $8.
09-14 18:37
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
08-07 20:30
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-07 05:20
InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per share from the same period last year.
08-06 19:33
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
InflaRx N.V., a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, will release its Q2 2026 financial and operational results on August 6, 2026, before market open. No conference call is scheduled. The company specializes in C5a and C5aR inhibitors, with lead programs izicopan and vilobelimab for inflammatory diseases. Founded in 2007, InflaRx has offices in Germany and the U.S.
07-30 11:30
InflaRx Mulls Feasibility For AAV In Europe
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessmen...
06-30 19:37
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
InflaRx is evaluating the feasibility of expanding its development and regulatory strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke Tavneos' marketing authorization. The company plans to engage with EMA regarding its anti-C5a antibody vilobelimab and next-generation oral C5aR inhibitor izicopan to assess the most efficient regulatory pathway for approval. Vilobelimab, approved under exceptional c...
06-30 11:30
